Journal
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Volume 75, Issue 6, Pages 516-525Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FJC.0000000000000744
Keywords
cardiovascular diseases; coronary artery disease; myocardial infarction; genetics; genome-wide association studies; cGMP
Funding
- Corona Foundation as part of the Junior Research Group Translational Cardiovascular Genomics [S199/10070/2017]
- German Research Foundation (DFG) [Sonderforschungsbereich SFB 1123]
Ask authors/readers for more resources
Cyclic guanosine 3 ',5 '-monophosphate (cGMP) is the key second messenger molecule in nitric oxide signaling. Its rapid generation and fate, but also its role in mediating acute cellular functions has been extensively studied. In the past years, genetic studies suggested an important role for cGMP in affecting the risk of chronic cardiovascular diseases, for example, coronary artery disease and myocardial infarction. Here, we review the role of cGMP in atherosclerosis and other cardiovascular diseases and discuss recent genetic findings and identified mechanisms. Finally, we highlight open questions and promising research topics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available